Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.
The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing.The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed.Clinicopathological, immunohistochemical markers (p53, p16, Ki-67, Her-2/neu and Home Coffee Machines EGF